prikaz prve stranice dokumenta Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms
  Preuzmi
PDF 1.19 MB
Znanstveni rad - Izvorni znanstveni rad
Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms
Acta Clinica Belgica, 76 (2021), 1; 32-39. https://doi.org/10.1080/17843286.2019.1659467
Krečak, Ivan; Gverić-Krečak, Velka; Lapić, Ivana; Rončević, Pavle; Gulin, Josipa; Fumić, Ksenija; Krečak, Filip; Holik, Hrvoje; Duraković, Nadira

Citirajte ovaj rad

Krečak, I., Gverić Krečak, V., Lapić, I., Rončević, P., Gulin, J., Fumić, K. ... Duraković, N. (2021). Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms. Acta Clinica Belgica, 76. (1), 32-39. doi: 10.1080/17843286.2019.1659467

Krečak, Ivan, et al. "Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms." Acta Clinica Belgica, vol. 76, br. 1, 2021, str. 32-39. https://doi.org/10.1080/17843286.2019.1659467

Krečak, Ivan, Velka Gverić Krečak, Ivana Lapić, Pavle Rončević, Josipa Gulin, Ksenija Fumić, Filip Krečak, Hrvoje Holik i Nadira Duraković. "Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms." Acta Clinica Belgica 76, br. 1 (2021): 32-39. https://doi.org/10.1080/17843286.2019.1659467

Krečak, I., et al. (2021) 'Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms', Acta Clinica Belgica, 76(1), str. 32-39. doi: 10.1080/17843286.2019.1659467

Krečak I, Gverić Krečak V, Lapić I, Rončević P, Gulin J, Fumić K, i sur.. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms. Acta Clinica Belgica [Internet]. 27.02.2021. [pristupljeno 19.12.2024.];76(1):32-39. doi: 10.1080/17843286.2019.1659467

I. Krečak, et al., "Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms", Acta Clinica Belgica, vol. 76, br. 1, str. 32-39, Veljača 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:965308. [Citirano: 19.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:965308
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms
AutorIvan Krečak
AutorVelka Gverić-Krečak
AutorIvana Lapić
AutorPavle Rončević
AutorJosipa Gulin
AutorKsenija Fumić
AutorFilip Krečak
AutorHrvoje Holik
AutorNadira Duraković
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Objectives: Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF), are characterized by clonal myeloproliferation and a strong inflammatory atmosphere. YKL-40, expressed in granulocytes, macrophages, megakaryocytes and malignant cells, is an acute phase reactant with an important role in tissue remodeling and atherosclerotic inflammation. The aim of this study was to investigate serum YKL-40 levels in MPNs and to assess its clinical correlations. ----- Methods: ELISA test was used to measure serum YKL-40 levels in 111 MPN patients and in 32 healthy controls. ----- Results: Serum YKL-40 levels were higher in ET, post-ET MF, PV, post-PV MF and primary MF patients, when compared to healthy controls (p < 0.001). Higher serum YKL-40 levels were associated with parameters indicative of the increased inflammatory state (higher C-reactive protein, poor performance status, presence of constitutional symptoms and cardiovascular risk factors). Additionally, higher serum YKL-40 levels in MF patients were associated with blast phase disease, lower hemoglobin and higher Dynamic International Prognostic Scoring System score. In the multivariate Cox regression models, higher serum YKL-40 levels in ET and PV patients were independently associated with an increased risk of thrombosis (HR 4.64, p = 0.031) and impaired survival in MF patients (HR 4.31, p = 0.038). ----- Conclusion: These results indicate that higher circulating YKL-40 levels in MPNs might have a pathophysiological role in disease progression and thrombosis development. Assessing circulating YKL-40 could help in identification of ET and PV patients at a high risk of future cardiovascular events and has a good potential for improving prognostication of MF patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaActa Clinica Belgica
Brojčani podacivol. 76, br. 1, str. 32-39
p-ISSN1784-3286
e-ISSN2295-3337
DOIhttps://doi.org/10.1080/17843286.2019.1659467
URN:NBNurn:nbn:hr:105:965308
Datum objave publikacije2021-02-27
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/17843286.2019.1659467
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Datum isteka embarga: 2022-03-01
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2021-02-17 09:34:34